Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study.
Saved in:
| Title: | Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study. |
|---|---|
| Authors: | Brizzi, M. P.1, Fazio, N.2, Ferrero, A.3, Nobili, E.4, Volante, M.5, Tozzi, L.6, D'Avolio, A.7, Milanesi, E.8, Dogliotti, L.1, Berruti, A.1 |
| Source: | Neuroendocrinology. Jul2012 Supplement, Vol. 96, p22-23. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00283835 |
|---|
